Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
07:00am, Tuesday, 12'th May 2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Thursday, 07'th May 2026
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
07:00am, Thursday, 07'th May 2026
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memor
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:01am, Wednesday, 06'th May 2026
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
02:29am, Sunday, 29'th Mar 2026
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will cont
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
06:55pm, Wednesday, 11'th Mar 2026
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
04:09pm, Wednesday, 11'th Mar 2026
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
04:26am, Wednesday, 11'th Mar 2026
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat.com re
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
07:00am, Monday, 23'rd Feb 2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
03:24am, Saturday, 14'th Feb 2026
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings report
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
07:00am, Tuesday, 03'rd Feb 2026
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
06:13am, Tuesday, 20'th Jan 2026
Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One
